Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth.
The Fibroblast Growth Factor 2 pipeline drugs market research report provides comprehensive information on the therapeutics under development for Fibroblast Growth Factor 2, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.
Fibroblast Growth Factor 2 Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas of the Fibroblast Growth Factor 2 pipeline drugs market are oncology, metabolic disorders, ophthalmology, cardiovascular, central nervous system, dermatology, immunology, and infectious disease.
Fibroblast Growth Factor 2 Pipeline Drugs Market Analysis, by Therapy Areas, 2022 (%)
For more therapy area insights into the Fibroblast Growth Factor 2 pipeline drugs market, download a free report sample
Fibroblast Growth Factor 2 Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action of the Fibroblast Growth Factor 2 pipeline drugs market are Fibroblast Growth Factor 2 Inhibitor, and Fibroblast Growth Factor 2 Activator.
Fibroblast Growth Factor 2 Pipeline Drugs Market Analysis, by Mechanisms of Action, 2022 (%)
For more mechanisms of action insights into the Fibroblast Growth Factor 2 pipeline drugs market, download a free report sample
Fibroblast Growth Factor 2 Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Fibroblast Growth Factor 2 pipeline drugs market are subcutaneous, intravitreal, intravenous, intramuscular, and topical.
Fibroblast Growth Factor 2 Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)
For more routes of administration insights into the Fibroblast Growth Factor 2 pipeline drugs market, download a free report sample
Fibroblast Growth Factor 2 Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Fibroblast Growth Factor 2 pipeline drugs market are small molecule, aptamer, cell therapy, fusion protein, gene therapy, and oncolytic virus.
Fibroblast Growth Factor 2 Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)
For more molecule type insights into the Fibroblast Growth Factor 2 pipeline drugs market, download a free report sample
Fibroblast Growth Factor 2 Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Fibroblast Growth Factor 2 pipeline drugs market are Zucero Therapeutics Ltd, Aurealis Therapeutics AG, ID Pharma Co Ltd, RemeGen Co Ltd, and Ribomic Inc.
Fibroblast Growth Factor 2 Pipeline Drugs Market Analysis, by Companies, 2022 (%)
To know more about the companies in the Fibroblast Growth Factor 2 pipeline drugs market, download a free report sample
Fibroblast Growth Factor 2 Pipeline Drugs Market Report Overview
Key Therapy Areas | Oncology, Metabolic Disorders, Ophthalmology, Cardiovascular, Central Nervous System, Dermatology, Immunology, and Infectious Disease |
Key Mechanisms of Action | Fibroblast Growth Factor 2 Inhibitor, and Fibroblast Growth Factor 2 Activator |
Key Routes of Administration | Subcutaneous, Intravitreal, Intravenous, Intramuscular, and Topical |
Key Molecule Types | Small Molecule, Aptamer, Cell Therapy, Fusion Protein, Gene Therapy, and Oncolytic Virus |
Leading Companies | Zucero Therapeutics Ltd, Aurealis Therapeutics AG, ID Pharma Co Ltd, RemeGen Co Ltd, and Ribomic Inc |
Segments Covered in the Report
Fibroblast Growth Factor 2 Pipeline Drugs Market Therapy Areas Outlook
- Oncology
- Metabolic Disorders
- Ophthalmology
- Cardiovascular
- Central Nervous System
- Dermatology
- Immunology
- Infectious Disease
Fibroblast Growth Factor 2 Pipeline Drugs Market Mechanisms of Action Outlook
- Fibroblast Growth Factor 2 Inhibitor
- Fibroblast Growth Factor 2 Activator
Fibroblast Growth Factor 2 Pipeline Drugs Market Routes of Administration Outlook
- Subcutaneous
- Intravitreal
- Intravenous
- Intramuscular
- Topical
Fibroblast Growth Factor 2 Pipeline Drugs Market Molecule Types Outlook
- Small Molecule
- Aptamer
- Cell Therapy
- Fusion Protein
- Gene Therapy
- Oncolytic Virus
Scope
- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
- The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
ID Pharma Co Ltd
RemeGen Co Ltd
Ribomic Inc
Zucero Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the Fibroblast Growth Factor 2 pipeline drugs market?
The key therapy areas of the Fibroblast Growth Factor 2 pipeline drugs market are oncology, metabolic disorders, ophthalmology, cardiovascular, central nervous system, dermatology, immunology, and infectious disease.
-
What are the key mechanisms of action in the Fibroblast Growth Factor 2 pipeline drugs market?
The key mechanism of action in the Fibroblast Growth Factor 2 pipeline drugs market are Fibroblast Growth Factor 2 Inhibitor, and Fibroblast Growth Factor 2 Activator.
-
What are the key routes of administration in the Fibroblast Growth Factor 2 pipeline drugs market?
The key routes of administration in the Fibroblast Growth Factor 2 pipeline drugs market are subcutaneous, intravitreal, intravenous, intramuscular, and topical.
-
What are the key molecule types in the Fibroblast Growth Factor 2 pipeline drugs market?
The molecule types in the Fibroblast Growth Factor 2 pipeline drugs market are small molecule, aptamer, cell therapy, fusion protein, gene therapy, and oncolytic virus.
-
Which are the leading companies in the Fibroblast Growth Factor 2 pipeline drugs market?
Some of the leading companies in the Fibroblast Growth Factor 2 pipeline drugs market are Zucero Therapeutics Ltd, Aurealis Therapeutics AG, ID Pharma Co Ltd, RemeGen Co Ltd, and Ribomic Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.